Drugs / GLUCAGON-LIKE PEPTIDE II
GLUCAGON-LIKE PEPTIDE II
also known as
GLP-2 · glucagon-like peptide 2 · 1-33-glucagon-like peptide ii · Glp-2 (1-33) · Glp-2 (human) · Glucagon-like Peptide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03682172 | May → Aug 2018 | gallbladder disorder | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01573286 | Jan 2012 → Aug 2014 | chronic intestinal failure, short bowel syndrome | Alberta Children's Hospital | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01958775 | Mar 2012 → Jun 2014 | hyperlipidemia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00273000 | Jan 2006 → ? | — | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT06194955 Comparator | Jan 2023 → Dec 2025 | hyperproglucagonemia | University of Copenhagen | Completed | No outcome recorded |
| — | NCT00673751 Comparator | — | short bowel syndrome | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | RANI Therapeutics | Results Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing ranitherapeutics.com ↗
The initial data demonstrated that oral RT-114 achieved systemic exposure exceeding that of matched subcutaneous administration, with a safety and tolerability profile consistent with the GLP-1/GLP-2 agonist class of therapeutics. |
| 2025-09-15 | Entera Bio Ltd. | Results Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress enterabio.com ↗
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy |
| 2025-07-14 | RANI Therapeutics | Results Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery ranitherapeutics.com ↗
Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines |
| 2025-03-26 | RANI Therapeutics | Results Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 ranitherapeutics.com ↗
PG-102 delivered orally via the RaniPill® capsule demonstrated comparable bioavailability and weight loss to subcutaneously (SC) injected PG-102 (“SC PG-102”). |
| 2024-03-28 | Ironwood Pharmaceuticals, Inc. | Results Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) ironwoodpharma.com ↗
Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study’s primary objective |
| 2024-03-20 | Entera Bio Ltd. | Results Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome enterabio.com ↗
The study’s objectives were met with oral GLP-2 tablets exhibiting significant systemic exposure. |
| 2023-10-16 | Ironwood Pharmaceuticals, Inc. | Results Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week ironwoodpharma.com ↗
Seventy-eight percent (78%) of patients gained one or more days off PS with all patients achieving clinical response. |
| 2023-06-16 | Hanmi Pharmaceutical Company Limited | Results 한미약품 “월1회 투여 희귀질환 혁신신약 개발 가능성 확인” hanmi.co.kr ↗
결과에 따르면 매일 혹은 주 1회 용법의 치료제를 투여하다, 월 1회 용법인 LAPS GLP-2 analog로 전환해 투여했을 때 더 우수한 효능이 나타났다. |
| 2021-09-13 | Hanmi Pharmaceutical Company Limited | Results “난치성 희귀질환 단장증후군 환자에게 혁신 치료옵션 제공” hanmi.co.kr ↗
이번에 발표된 연구 결과에 따르면, 매일 투여해야 하는 유일한 단장증후군 치료제 또는 현재 개발중인 주1회 지속형 치료제를 투약중인 모델에 비해 LAPS GLP-2 Analog를 한달에 한 번 투약한 그룹에서 소장의 성장 및 흡수능력이 더 증가하는 것으로 확인됐다. |
| 2021-04-07 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> FDA, 한미약품 단장증후군 치료 혁신신약 패스트트랙 지정 hanmi.co.kr ↗
한미약품이 개발 중인 희귀질환 치료제인 LAPSGLP-2 Analog(HM15912)가 FDA로부터 패스트트랙으로 지정됐다. |
| 2021-01-21 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미약품 희귀질환치료 혁신신약 2종, FDA 임상2상 승인 hanmi.co.kr ↗
한미약품(대표이사 권세창？우종수)이 최근 JP모건 컨퍼런스에서 발표한 희귀질환 치료 혁신신약 LAPS Glucagon Analog(HM15136)와 LAPS GLP-2 Analog(HM15912)에 대해 미국 FDA가 임상 2상을 승인했다. |
| 2020-06-30 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미 <sup>LAPS</sup>GLP-2 Analog, 美 FDA 소아 희귀의약품 지정 hanmi.co.kr ↗
한미약품은 단장증후군 치료 바이오신약으로 독자 개발중인 LAPS GLP-2 Analog(코드명: HM15912)가 미국 FDA로부터 희귀 소아 질병 의약품(Rare Pediatric Disease Designation, 이하 RPD ⅰ )으로 추가 지정됐다고 30일 밝혔다. |
| 2019-05-03 | Hanmi Pharmaceutical Company Limited | Regulatory <보도자료> 한미약품 단장증후군 치료 신약, 美 FDA 희귀의약품 지정 hanmi.co.kr ↗
한미약품이 독자적 플랫폼 기술인 랩스커버리를 적용해 단장증후군 치료 바이오 신약으로 개발중인 LAPS GLP-2 Analog(코드명 : HM15912)가 지난 1일 미국 FDA로부터 희귀의약품으로 지정됐다. |
| 2016-05-27 | Takeda | Regulatory Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome takeda.com ↗
“We are delighted that the CHMP has rendered a favorable recommendation for teduglutide in paediatric patients based on their evaluation of the data and benefit-to-risk balance,” said Philip J. Vickers, Ph.D., Head of Research and Development, Shire. |
All press releases naming this drug 23 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLUCAGON-LIKE PEPTIDE II | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958 ↗ |
| Known as | 1-33-glucagon-like peptide ii | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958 ↗ |
| Known as | GLP-2 | “GLP-2 (1-33) is a naturally occurring peptide which is important in controlling the function of the intestine.” NCT01573286 ↗ |
| Known as | Glp-2 (1-33) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958 ↗ |
| Known as | Glp-2 (human) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297958 ↗ |
| Known as | Glucagon-like Peptide | “The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome” NCT00673751 ↗ |
| Known as | glucagon-like peptide 2 | “The study will investigate the effect of the incretin hormone glucagon-like peptide 2 (GLP-2) on postprandial gallbladder motility in young, healthy, male subjects.” NCT03682172 ↗ |
| Modality | Peptide | “GLP-2 (1-33) is a naturally occurring peptide” NCT01573286 ↗ |
| Route | Intravenous | “administered intraveneous GLP-2” NCT00273000 ↗ |